The histone modification patterns in endometriosis have not been fully characterized. This gap in knowledge results in a poor understanding of the epigenetic mechanisms (and potential therapeutic targets) at play. We aimed to (1) assess global acetylation status of histone 3 (H3) and histone 4 (H4), (2) measure levels of H3 and H4 lysine (K) acetylation and methylation, and (3) to identify histone acetylation patterns in promoter regions of candidate genes in tissues from patients and controls.
Methods:
Global and K-specific acetylation/methylation levels of histones were measured in 24 lesions, 15 endometrium from patients, and 26 endometrium from controls. Chromatin immunoprecipitation (ChIP)–polymerase chain reaction was used to determine the histone acetylation status of the promoter regions of candidate genes in tissues.
Results:
The lesions were globally hypoacetylated at H3 (but not H4) compared to eutopic endometrium from controls. Lesions had significantly lower levels of H3K9ac and H4K16ac compared to eutopic endometrium from patients and controls. Tissues from patients were hypermethylated at H3K4, H3K9, and H3K27 compared to endometrium from controls. The ChIP analysis showed hypoacetylation of H3/H4 within promoter regions of candidate genes known to be downregulated in endometriosis (e.g., HOXA10,ESR1, CDH1, and p21WAF1/Cip1) in lesions versus control endometrium. The stereoidogenic factor 1 (SF1) promoter region was enriched for acetylated H3 and H4 in lesions versus control tissues, correlating with its reported high expression in lesions.
Conclusions:
This study describes the histone code of lesions and endometrium from patients with endometriosis and provides support for a possible role of histone modification in modulation of gene expression in endometriosis.
BulunSE. Endometriosis. N Engl J Med. 2009;360(3):268–279.
2.
GiudiceLC. Genomics' role in understanding the pathogenesis of endometriosis. Semin Reprod Med. 2003;21(2):119–124.
3.
KaoLCGermeyerATulacSExpression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility. Endocrinology. 2003;144(7):2870–2881.
4.
GuoSW. Epigenetics of endometriosis. Mol Hum Reprod. 2009;15(10):587–607.
5.
JenuweinTAllisCD. Translating the histone code. Science. 2001;293(5532):1074–1080.
6.
TurnerBM. Cellular memory and the histone code. Cell. 2002;111(3):285–291.
7.
FergusonLRTathamALLinZDennyWA. Epigenetic regulation of gene expression as an anticancer drug target. Curr Cancer Drug Targets. 2011;11(2):199–212.
8.
WuYStarzinski-PowitzAGuoSW. Trichostatin A, a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalized endometriotic cells. Reprod Sci. 2007;14(4):374–382.
9.
WuYGuoSW. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol. 2008;137(2):198–203.
10.
LiuMLiuXZhangYGuoSW. Valproic acid and progestin inhibit lesion growth and reduce hyperalgesia in experimentally induced endometriosis in rats. Reprod Sci. 2012;19(4):360–373.
11.
Colón-DíazMBáez-VegaPGarcíaMHDAC1 and HDAC2 are differentially expressed in endometriosis. Reprod Sci. 2012;19(5):483–492.
12.
TurnerBM. Histone acetylation and an epigenetic code. Bioessays. 2000;22(9):836–845.
13.
StrahlBDAllisCD. The language of covalent histone modifications. Nature. 2000;403(6765):41–45.
14.
GardnerKEAllisCDStrahlBD. Operating on chromatin, a colorful language where context matters. J Mol Biol. 2011;409(1):36–46.
15.
RobyrDKurdistaniSKGrunsteinM. Analysis of genome-wide histone acetylation state and enzyme binding using DNA microarrays. Methods Enzymol. 2004;376:289–304.
ChenCZhaoMYinNAbnormal histone acetylation and methylation levels in esophageal squamous cell carcinomas. Cancer Invest. 2011;29(8):548–556.
18.
TabyRIssaJP. Cancer epigenetics. CA Cancer J Clin. 2010;60(6):376–392.
19.
DiekerJWFransenJHvan BavelCCApoptosis-induced acetylation of histones is pathogenic in systemic lupus erythematosus. Arthritis Rheum. 2007;56(6):1921–1933.
20.
HuNQiuXLuoYAbnormal histone modification patterns in lupus CD4+ T cells. J Rheumatol. 2008;35(5):804–810.
21.
DaiYZhangLHuCZhangY. Genome-wide analysis of histone H3 lysine 4 trimethylation by ChIP-chip in peripheral blood mononuclear cells of systemic lupus erythematosus patients. Clin Exp Rheumatol. 2010;28(2):158–168.
22.
DenkFMcMahonSB. Chronic pain: emerging evidence for the involvement of epigenetics. Neuron. 2012;73(3):435–444.
23.
FischerJJToedlingJKruegerTSchuelerMHuberWSperlingS. Combinatorial effects of four histone modifications in transcription and differentiation. Genomics. 2008;91(1):41–51.
24.
NoyesRWHertigATRockJ. Dating the endometrial biopsy. Am J Obstet Gynecol. 1975;122(2):262–263.
25.
YostJMKorboukhILiuFGaoCJinJ. Targets in epigenetics: inhibiting the methyl writers of the histone code. Curr Chem Genomics. 2011;5(suppl 1):72–84.
26.
JeffriesMASawalhaAH. Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents. Int J Clin Rheumatol. 2011;6(4):423–439.
27.
HakeSBXiaoAAllisCD. Linking the epigenetic ‘language' of covalent histone modifications to cancer. Br J Cancer. 2007;96(suppl):R31–R39.
28.
WangGG, Allis CD. “Misinterpretation” of a histone mark is linked to aberrant stem cells and cancer development. Cell Cycle. 2009;8(13):1982–1983.
29.
ChenHHardyTMTollefsbolTO. Epigenomics of ovarian cancer and its chemoprevention. Front Genet. 2011;2:67.
30.
KurdistaniSKTavazoieSGrunsteinM. Mapping global histone acetylation patterns to gene expression. Cell. 2004;117(6):721–733.
31.
BakerLAAllisCDWangGG. PHD fingers in human diseases: disorders arising from misinterpreting epigenetic marks. Mutat Res. 2008;647(1-2):3–12.
32.
WangGGAllisCDChiP. Chromatin remodeling and cancer, Part I: Covalent histone modifications. Trends Mol Med. 2007;13(9):363–372.
33.
MosashvilliDKahlPMertensC, Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. Cancer Sci. 2010;101(12):2664–2669.
34.
ZhangPSuYZhaoMHuangWLuQ. Abnormal histone modifications in PBMCs from patients with psoriasis vulgaris. Eur J Dermatol. 2011;21(4):552–557.
35.
SunHSHsiaoKYHsuCCWuMHTsaiSJ. Transactivation of steroidogenic acute regulatory protein in human endometriotic stromalcells is mediated by the prostaglandin EP2 receptor. Endocrinology. 2003;144(9):3934–3942.
36.
GiacintiLClaudioPPLopezMGiordanoA. Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist. 2006;11(1):1–8.
37.
CaoDBrombergPASametJM. COX-2 expression induced by diesel particles involves chromatin modification and degradation of HDAC1. Am J Respir Cell Mol Biol. 2007;37(2):232–239.
38.
CowardWRWattsKFeghali-BostwickCAKnoxAPangL. Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol Cell Biol. 2009;29(15):4325–4339.
39.
MitaniYOueNHamaiYAungPPHistone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma. J Pathol. 2005;205(1):65–73.
40.
XiaomengXMingZJiezhiMXiaolingF. Aberrant histone acetylation and methylation levels in woman with endometriosis. Arch Gynecol Obstet. 2013;287(3):487–494.
41.
LuYNieJLiuXZhengYGuoSW. Trichostatin A, a histone deacetylase inhibitor, reduces lesion growth and hyperalgesia in experimentally induced endometriosis in mice. Hum Reprod. 2010;25(4):1014–1025.
42.
SchübelerDMacAlpineDMScalzoDThe histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev. 2004;18(11):1263–1271.
43.
GrandjeanVO'NeillLSadoTTurnerBFerguson-SmithA. Relationship between DNA methylation, histone H4 acetylation and gene expression in the mouse imprinted Igf2-H19 domain. FEBS Lett. 2001;488(3):165–169.
44.
WangZZangCRosenfeldJACombinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008;40(7):897–903.
45.
BernsteinBEKamalMLindblad-TohKGenomic maps and comparative analysis of histone modifications in human and mouse. Cell. 2005;120(2):169–181.
46.
NishidaHSuzukiTKondoSMiuraHFujimuraYHayashizakiY. Histone H3 acetylated at lysine 9 in promoter is associated with low nucleosome density in the vicinity of transcription start site in human cell. Chromosome Res. 2006;14(2):203–211.
47.
HeintzmanNDHonGCHawkinsRDHistone modifications at human enhancers reflect global cell-type-specific gene expression. Nature. 2009;459(7243):108–112.
48.
RohTYNgauWCCuiKLandsmanDZhaoK. High-resolution genome-wide mapping of histone modifications. Nat Biotechnol. 2004;22(8):1013–1016.
49.
KondoYShenLIssaJP. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol. 2003;23(1):206–215.
50.
VossAKCollinCDixonMPThomasT.Moz and retinoic acid coordinately regulate H3K9 acetylation, Hox gene expression, and segment identity. Dev Cell. 2009;17(5):674–686.
51.
MohamedMAGreifPADiamondJEpigenetic events, remodelling enzymes and their relationship to chromatin organization in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. BJU Int. 2007;99(4):908–915.
52.
SeligsonDBHorvathSMcBrianMAGlobal levels of histone modifications predict prognosis in different cancers. Am J Pathol. 2009;174(5):1619–1628.
53.
SeligsonDBHorvathSShiTGlobal histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005;435(7046):1262–1266.
54.
BarlésiFGiacconeGGallegos-RuizMIGlobal histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol. 2007;25(28):4358–4564.
55.
AbujamraALDos SantosMPRoeslerRSchwartsmannGBrunettoAL. Histone deacetylase inhibitors: a new perspective for the treatment of leukemia. Leuk Res. 2010;34(6):687–695.
56.
KrejcíJUhlírováRGaliováGKozubekSSmigováJBártováE. Genome-wide reduction in H3K9 acetylation during human embryonic stem cell differentiation. J Cell Physiol. 2009;219(3):677–687.
57.
SadikovicBAndrewsJCarterDRobinsonJRodenhiserDI. Genome-wide H3K9 histone acetylation profiles are altered in benzopyrene-treated MCF7 breast cancer cells. J Biol Chem. 2008;283(7):4051–4060.
58.
SadikovicBAndrewsJCarterDRobinsonJRodenhiserDI. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37(4):391–400.
59.
PfisterSReaSTaipaleMThe histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int J Cancer. 2008;122(6):1207–1213.
60.
Kapoor-VaziraniPKageyJDPowellDRVertinoPM. Role of hMOF-dependent histone H4 lysine 16 acetylation in the maintenance of TMS1/ASC gene activity. Cancer Res. 2008;68(16):6810–6821.
61.
HeCXuJZhangJHigh expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Human Pathol. 2012;43(9):1425–1435.
62.
EllingerJKahlPvon der GathenJGlobal levels of histone modifications predict prostate cancer recurrence. Prostate. 2010;70(1):61–69.
BernsteinBEMikkelsenTSXieXA bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 2006;125(2):315–326.
65.
KhromovTPantakaniDVNolteJGlobal and gene-specific histone modification profiles of mouse multipotent adult germline stem cells. Mol Hum Reprod. 2011;17(3):166–174.
66.
PflugerJWagnerD. Histone modifications and dynamic regulation of genome accessibility in plants. Curr Opin Plant Biol. 2007;10(6):645–652.
67.
KatohHQinZSLiuRFOXP3 orchestrates H4K16 acetylation and H3K4 trimethylation for activation of multiple genes by recruiting MOF and causing displacement of PLU-1. Mol Cell. 2011;44(5):770–784.
68.
SeeberLMvan DiestPJ. Epigenetics in ovarian cancer. Methods Mol Biol. 2012;863:253–269.
69.
CreaF. Histone code, human growth and cancer. Oncotarget. 2012;3(1):1–2.
70.
MunroSKFarquharCMMitchellMDPonnampalamAP. Epigenetic regulation of endometrium during the menstrual cycle. Mol Hum Reprod. 2010;16(5):297–310.
71.
SakaiNMaruyamaTSakuraiRInvolvement of histone acetylation in ovarian steroid-induced decidualization of human endometrial stromal cells. J Biol Chem. 2003;278(19):16675–16682.
72.
KooistraSMHelinK. Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol. 2012;13(5):297–311.
73.
BrykczynskaUHisanoMErkekSRepressive and active histone methylation mark distinct promoters in human and mouse spermatozoa. Nat Struct Mol Biol. 2010;17(6):679–687.
74.
MargueronRReinbergD. Chromatin structure and the inheritance of epigenetic information. Nat Rev Genet. 2010;11(4):285–296.
75.
ZhuB, Reinberg D. Epigenetic inheritance: uncontested? Cell Res. 2011;21(3):435–441.
76.
FeinbergAP. An epigenetic approach to cancer etiology. Cancer j. 2007;13(1):70–74.
77.
TaylorHSAriciAOliveDIgarashiP. HOXA10 is expressed in response to sex steroids at the time of implantation in the human endometrium. J Clin Invest. 1998;101(7):1379–1384.
78.
TroianoRNTaylorKJ. Sonographically guided therapeutic aspiration of benign-appearing ovarian cysts and endometriomas. AJR Am J Roentgenol. 1998;171(6):1601–1605.
79.
WuYHalversonGBasirZStrawnEYanPGuoSW. Aberrant methylation at HOXA10 may be responsible for its aberrant expression in the endometrium of patients with endometriosis. Am J Obstet Gynecol. 2005;193(2):371–380.
80.
YoshikawaMHishikawaKMarumoTFujitaT. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol. 2007;18(1):58–65.
81.
XueQLinZChengYHPromoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis. Biol Reprod. 2007;77(4):681–687.
82.
XueQLinZYinPTranscriptional activation of steroidogenic factor-1 by hypomethylation of the 5′ CpG island in endometriosis. J Clin Endocrinol Metab. 2007;92(8):3261–3267.
83.
NoonanEJPlaceRF, Pookot D, et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene. 2009;28(14):1714–1724.
